Checks whether common drugs affect lung cancer immunotherapy survival
Reviews past records of lung cancer patients on immunotherapy who took gut-altering drugs.
Key facts
- Who runs it
- University Hospital, Strasbourg, France
- Where
- Strasbourg, FranceSee the site
- Trial code
- Registry title
- Impact of Dysbiosis-inducing Drugs on Effectivity of Immune Checkpoint Inhibitor in Non-small Cell Lung Cancer Patients
- Status
- Recruiting
- People taking part
- 800 people, planned
- Started
- 5 Feb 2025
- Planned end
- 5 Feb 2026
- Type of study
- Observational
- Record updated
- 24 September 2025
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with non-small cell lung cancer (NSCLC) at stage III-C or stage IV who are treated with immunotherapy. It is a study of past patient records.
- Age
- 18 years or older
- Sex
- All sexes can join
- Disease stage
- Non-small cell lung cancer (NSCLC) at stage III-C or stage IV
- Earlier treatment
- Treated with immunotherapy
Main reasons for not taking part
- Refused to let their data be reused for scientific research
- Under 18 years old
- Disease stage below stage III-C
- Included in a clinical trial with an unknown randomization arm (double-blind study)
- Not enough data on other treatments, biology, or clinical outcomes
The registry criteria, word for word
Show all 9 criteriaShow less
Who can take part
- Adult (≥18 years)
- Confirmed diagnosis of NSCLC
- Stage IV or stage III-C NSCLC
- Immunotherapy treatment
Who cannot take part
- Lack of relevant data on concomitant treatments, biology, or clinical outcomes
- Disease stage below stage III-C
- Refusal to reuse data for scientific research purposes
- Minor patient
- Patient included in a clinical trial with an unknown randomization arm (double-blind study)
Where in France
- Service de Pneumologie - CHU de Strasbourg - FranceStrasbourg, FranceContact: Céline MASCAUX, MD, PhDTaking people
About the trial
What the trial wants to find out
Lung cancer is the leading cancer in France in terms of mortality. The prognosis of the disease is closely correlated with the diagnostic stage and the majority of patients are diagnosed at a metastatic stage. The arrival of immunotherapy has made it possible to change the therapeutic paradigm by significantly improving the survival of metastatic patients. Despite this progress, only 20 to 30% of patients respond to immunotherapy. The search for predictive factors of response to or resistance to these drugs is of major importance for better patient selection. Among these factors, the intestinal microbiota appears to be closely correlated with the response to immunotherapy via the education of adaptive anticancer immunity. Thus, several bacterial species have been associated with patient survival or disease progression. Interestingly, the abundance of these same bacteria can be modulated by certain drugs co-prescribed with immunotherapy. These dysbiotic treatments or those leading to a significant modification of the composition of the intestinal microbiota could then modulate the response to immunotherapy and therefore patient survival. The objective of this study is therefore to objectify the impact of several therapeutic classes modifying the intestinal microbiota initiated in the 90 days preceding D1 of immunotherapy on the survival of patients with locally advanced (stage III-C) or metastatic (stage IV) non-small cell lung cancer (NSCLC)
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Impact of Dysbiosis-inducing Drugs on Effectivity of Immune Checkpoint Inhibitor in Non-small Cell Lung Cancer Patients: a Retrospective Study
- Plain-language title
- Checks whether common drugs affect lung cancer immunotherapy survivalGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 24 September 2025